FI953926A0 - Hormonin palautushoito - Google Patents

Hormonin palautushoito

Info

Publication number
FI953926A0
FI953926A0 FI953926A FI953926A FI953926A0 FI 953926 A0 FI953926 A0 FI 953926A0 FI 953926 A FI953926 A FI 953926A FI 953926 A FI953926 A FI 953926A FI 953926 A0 FI953926 A0 FI 953926A0
Authority
FI
Finland
Prior art keywords
replacement therapy
hormone replacement
estrogen
antiprogestin
woman
Prior art date
Application number
FI953926A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI953926A (fi
Inventor
Gary D Hodgen
Original Assignee
Hampton Roads Medical College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21816657&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI953926(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hampton Roads Medical College filed Critical Hampton Roads Medical College
Publication of FI953926A0 publication Critical patent/FI953926A0/fi
Publication of FI953926A publication Critical patent/FI953926A/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Steroid Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Dental Preparations (AREA)
  • Prostheses (AREA)
FI953926A 1993-02-25 1995-08-22 Hormonin palautushoito FI953926A (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/023,692 US5468736A (en) 1993-02-25 1993-02-25 Hormone replacement therapy
PCT/US1994/001815 WO1994018983A1 (en) 1993-02-25 1994-02-18 Hormone replacement therapy

Publications (2)

Publication Number Publication Date
FI953926A0 true FI953926A0 (fi) 1995-08-22
FI953926A FI953926A (fi) 1995-08-22

Family

ID=21816657

Family Applications (1)

Application Number Title Priority Date Filing Date
FI953926A FI953926A (fi) 1993-02-25 1995-08-22 Hormonin palautushoito

Country Status (25)

Country Link
US (1) US5468736A (de)
EP (1) EP0686037B1 (de)
JP (1) JP3441459B2 (de)
KR (1) KR100248857B1 (de)
AT (1) ATE202281T1 (de)
AU (1) AU680239B2 (de)
BG (1) BG62383B1 (de)
BR (1) BR9406667A (de)
CA (1) CA2157003C (de)
CZ (1) CZ290562B6 (de)
DE (1) DE69427529T2 (de)
DK (1) DK0686037T3 (de)
ES (1) ES2159552T3 (de)
FI (1) FI953926A (de)
GR (1) GR3036649T3 (de)
HU (1) HU221169B1 (de)
NO (1) NO309456B1 (de)
NZ (1) NZ262657A (de)
PL (1) PL176796B1 (de)
PT (1) PT686037E (de)
RO (1) RO115115B1 (de)
RU (1) RU2139056C1 (de)
SK (1) SK282921B6 (de)
UA (1) UA43842C2 (de)
WO (1) WO1994018983A1 (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9301121A (es) 1992-03-02 1993-09-01 Schering Ag Metodo y equipo para la contracepcion oral y regulacion de la menstruacion con estrogeno/progestina/aniprogestina.
US7704983B1 (en) 1992-03-02 2010-04-27 Eastern Virginia Medical School Antiprogestin method for reducing side effects associated with low dosage HRT and oral contraception
US6407082B1 (en) 1996-09-13 2002-06-18 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of a vitamin D compound
AU5942700A (en) * 1996-03-11 2000-11-30 Schering Aktiengesellschaft Sequential estrogen/progestrone antagonist combination for hormone replacement theapy
DE19610635A1 (de) * 1996-03-11 1997-09-18 Schering Ag Sequentielle Estrogen/Progesteronantagonist-Kombination für die Hormonersatz-Therapie
US6028064A (en) 1996-09-13 2000-02-22 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of progestin products
US6034074A (en) 1996-09-13 2000-03-07 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of a Vitamin D compound
US6511970B1 (en) 1996-09-13 2003-01-28 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of products that induce transforming growth factor-beta and/or apoptosis in the ovarian epithelium
US6765002B2 (en) 2000-03-21 2004-07-20 Gustavo Rodriguez Prevention of ovarian cancer by administration of products that induce transforming growth factor-β and/or apoptosis in the ovarian epithelium
US20060014728A1 (en) * 1996-11-21 2006-01-19 Kristof Chwalisz Hormone replacement therapy
US5855920A (en) * 1996-12-13 1999-01-05 Chein; Edmund Y. M. Total hormone replacement therapy
CZ301412B6 (cs) 1999-08-31 2010-02-24 Bayer Schering Pharma Aktiengesellschaft Použití specifických mesoprogestinu jako farmaceutické složky pro výrobu léciva pro hormonální substitucní lécbu
US7629334B1 (en) 1999-08-31 2009-12-08 Bayer Schering Pharma Aktiengesellschaft Mesoprogrestins (progesterone receptor modulations) as a component of compositions for hormone replacement therapy (HRT)
US6432643B1 (en) * 1999-10-22 2002-08-13 Duke University Method of determining Alzheimer's disease risk using apolipoprotein E4 genotype analysis in combination with decreased estrogen levels
US20010044431A1 (en) * 2000-03-21 2001-11-22 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
US20040176336A1 (en) * 2000-03-21 2004-09-09 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
US20050113351A1 (en) * 2000-03-21 2005-05-26 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
EP1260225A1 (de) * 2001-05-18 2002-11-27 Pantarhei Bioscience B.V. Pharmazeutische Zusammensetzung für die Hormonersatztherapie
US8048869B2 (en) * 2001-05-18 2011-11-01 Pantarhei Bioscience B.V. Pharmaceutical composition for use in hormone replacement therapy
PT1390042E (pt) * 2001-05-23 2008-03-10 Pantarhei Bioscience Bv Sistema de administração de um medicamento que compreende estrogénio tetrahidroxilado destinado à contracepção hormonal
ATE449606T1 (de) * 2001-05-23 2009-12-15 Pantarhei Bioscience Bv Tetrahydroxylierte estrogen enthaltendes arzneistoffverabreichungssystem zur verwendung in hormonalen kontrazeption
WO2003018026A1 (en) * 2001-08-31 2003-03-06 Pantarhei Bioscience B.V. Use of estrogenic compounds in combination with progestogenic compounds in hormone-replacement therapy
WO2003041718A1 (en) * 2001-11-15 2003-05-22 Pantarhei Bioscience B.V. Use of estrogenic compounds in combination with progestogenic compounds in hormone-replacement therapy
DE10206089A1 (de) 2002-02-13 2002-08-14 Zimmer Ag Bersteinsatz
US7923440B2 (en) * 2002-06-11 2011-04-12 Pantarhei Bioscience B.V. Method of treating or preventing immune mediated disorders and pharmaceutical formulation for use therein
US7943604B2 (en) * 2002-06-11 2011-05-17 Pantarhei Bioscience B.V. Method of treating human skin and a skin care composition for use in such a method
AU2003253506A1 (en) * 2002-07-12 2004-02-02 Pantarhei Biosciences B.V. Pharmaceutical composition comprising estetrol derivatives for use in cancer therapy
SI1556058T1 (sl) * 2002-10-23 2008-02-29 Pantarhei Bioscience Bv Farmacevtski sestavki, ki obsegajo estetrolne derivate, za uporabo pri zdravljenju raka
DE602004002591T9 (de) * 2003-05-22 2008-01-03 Pantarhei Bioscience B.V. Verwendung von zusammensetzungen enthaltend ein oestrogen zur behandlung und verhinderung von muskelskelettschmerzen
SI3263112T1 (sl) * 2006-10-24 2020-10-30 Allergan Pharmaceuticals International Limited Sestavki in metode za zaviranje endometrijskih proliferacij
CA2674325A1 (en) * 2007-01-08 2008-07-17 Pantarhei Bioscience B.V. Method of treating or preventing infertility in a female mammal and pharmaceutical kit for use in such method
US20080293683A1 (en) * 2007-05-24 2008-11-27 University Of Kansas Medical Center Hormone Replacement Therapy
HUE055562T2 (hu) 2011-11-23 2021-11-29 Therapeuticsmd Inc Természetes kombinációjú hormon helyettesítõ kiszerelések, és terápiák ezekkel
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
RU2016143081A (ru) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. Натуральные комбинированные гормонозаместительные составы и терапии
WO2016090139A1 (en) * 2014-12-03 2016-06-09 Evestra, Inc. Combination of estrogens plus antiprogestins with significant partial agonistic effect as an effective treatment of menopausal symptoms and for prevention of the occurrence of breast cancer
EA035687B1 (ru) 2015-06-18 2020-07-27 Эстетра Спрл Диспергируемая в полости рта единица дозирования, содержащая эстетрольный компонент
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
KR20180126582A (ko) 2016-04-01 2018-11-27 쎄러퓨틱스엠디, 인코퍼레이티드 스테로이드 호르몬 약제학적 조성물
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3890356A (en) * 1973-03-26 1975-06-17 Richardson Merrell Inc 7-Alkyl-{66 {hu 3,5{b -steroids
US3928398A (en) * 1973-11-01 1975-12-23 Richardson Merrell Inc Derivatives of 7{60 -methylestr-4-en-3{60 ,17{62 -diol
US4416822A (en) * 1982-07-09 1983-11-22 The Upjohn Company 17β-Difluoromethyl steroids
IL68222A (en) * 1983-03-24 1987-02-27 Yeda Res & Dev Contraceptive compositions comprising a progesterone antagonist and a blocker of progesterone activity
AU572589B2 (en) * 1983-12-14 1988-05-12 Upjohn Company, The 11(alpha)-difluoromethyl and (e)-and (z)-11-fluoromethylene steroids
MX9301121A (es) * 1992-03-02 1993-09-01 Schering Ag Metodo y equipo para la contracepcion oral y regulacion de la menstruacion con estrogeno/progestina/aniprogestina.

Also Published As

Publication number Publication date
CZ204895A3 (en) 1996-03-13
WO1994018983A1 (en) 1994-09-01
BG62383B1 (bg) 1999-10-29
UA43842C2 (uk) 2002-01-15
PL310660A1 (en) 1995-12-27
HU9502306D0 (en) 1995-09-28
JP3441459B2 (ja) 2003-09-02
JPH08510993A (ja) 1996-11-19
GR3036649T3 (en) 2001-12-31
HUT72080A (en) 1996-03-28
AU6245494A (en) 1994-09-14
ES2159552T3 (es) 2001-10-16
KR100248857B1 (ko) 2000-04-01
CA2157003C (en) 2001-04-17
DE69427529D1 (de) 2001-07-26
AU680239B2 (en) 1997-07-24
FI953926A (fi) 1995-08-22
EP0686037A1 (de) 1995-12-13
KR960700727A (ko) 1996-02-24
RO115115B1 (ro) 1999-11-30
NO953243D0 (no) 1995-08-17
ATE202281T1 (de) 2001-07-15
BR9406667A (pt) 1996-01-23
EP0686037A4 (de) 1997-11-26
SK104995A3 (en) 1997-04-09
CA2157003A1 (en) 1994-09-01
EP0686037B1 (de) 2001-06-20
US5468736A (en) 1995-11-21
HU221169B1 (en) 2002-08-28
DE69427529T2 (de) 2001-11-22
NO309456B1 (no) 2001-02-05
SK282921B6 (sk) 2003-01-09
PL176796B1 (pl) 1999-07-30
BG99880A (bg) 1996-02-28
NO953243L (no) 1995-08-17
DK0686037T3 (da) 2001-08-27
CZ290562B6 (cs) 2002-08-14
NZ262657A (en) 1997-05-26
RU2139056C1 (ru) 1999-10-10
PT686037E (pt) 2001-09-28

Similar Documents

Publication Publication Date Title
DK0686037T3 (da) Hormonsubstitutionsterapi
US5460820B1 (en) Method for providing testosterone and optionally estrogen replacement therapy to women
PT1011781E (pt) Stent com arco
MY113079A (en) Estrogen agonists as remedies for cardiovascular diseases
BG101349A (en) Combination of prostacyclin with an estrogen or progestin for the prevention and treatment of atherosclerotic vascular disease including preeclampsia and for the treatment of hypertension, and for hormone replacement therapy
DE69710896D1 (en) Progestogen-anti-progestogen therapien
PL327146A1 (en) Antagonists of the gonadotrophin liberating hormone
GR3019289T3 (en) Steroid sulphatase inhibitors
ZA951880B (en) Transdermal system in the form of a patch comprising a tamoxifen derivative
EP0642261A3 (de) Spannungsregler für die Versorgung der Elektrode einer Kathodenstrahlröhre.
EA199700449A1 (ru) Способ предотвращения остеопороза
ES2141044A1 (es) Terapia con oxibutinina.
AU5110896A (en) Once-a-month-injection as a depot contraceptive and for hormone replacement therapy for perimenopausal and premenopausal women
SU1250153A1 (ru) Устройство для сверхвысокочастотного нагрева
MX9709013A (es) Forma de dosis que comprende oxibutinina.
JO1748B1 (en) New polypeptide derivatives
SU1223536A2 (ru) Установка для электронно-лучевой сварки
JO1745B1 (en) Circuit scale
JO1813B1 (en) Slicing and forming cakes and covered with sesame
MX9707082A (es) Fuente luminosa de linea que incluye un colorante fluorescente.

Legal Events

Date Code Title Description
FD Application lapsed

Free format text: GIP GENERAL INNOVATION PARTNERS LTD